Foresite Capital’s Post

Congratulations to Molly He and the team at Element Biosciences on their oversubscribed series D financing! We are proud to partner with this team as they push forward with disruptive DNA sequencing and multi-omics technologies to reshape our industry.

So happy to share that Drs. Hyung Chun and Cindy (Xin) Xiong are now partners at Foresite Capital! Their contributions and leadership have been pivotal in shaping our investment strategies in healthcare and life sciences over the years. Since joining us in 2021, Hyung has brought his extensive expertise as a physician-scientist from Yale School of Medicine and serves on the board of multiple Foresite portfolio companies including Latigo Biotherapeutics, Inc.. Cindy joined our team in 2019, and has been a trailblazer in biotech innovation. She serves on the boards of several portfolio companies including ImmPACT Bio and previously Xinthera, Inc. (board observer, acquired by Gilead). As partners, Hyung and Cindy will lead investments in a wide range of therapeutic areas. Read about their new roles at the link below.

This is a wonderful program, and it's a quick application process. Please help us spread the word to any aspiring VCs from underrepresented backgrounds interested in the life sciences track.

Nice write-up on our Fund VI close from the team at Fierce Biotech. Our CEO Jim Tananbaum says this is “one of the best biotech investment environments” of his multi-decade career. Read more at the link below.

With the closing of our sixth fund at $900 million, we're excited to continue supporting pioneering technologies at the intersection of technology and biotech. Fund VI has invested in companies including Alumis, CG Oncology, Latigo Biotherapeutics, Inc., and Xaira Therapeutics. These companies are redefining what's possible in medicine; from novel treatments to cutting-edge technologies, their efforts are paving the way for a healthier future. We're inspired by the visionary entrepreneurs we work with and grateful for the continued support of our investors. Learn more about Fund VI via Michael Bodley for PitchBook.

Sharing a fun clip on the proper pronunciation of our portfolio company Xaira Therapeutics by one of their scientists.

Our portfolio company Mirvie was featured on TODAY.com, highlighting their precision medicine approach to identify those at risk for pregnancy complications and avoid situations like what happened to Lindsay. Women's health is an underserved area and one we are proud to support through companies like Mirvie.

Welcome to our portfolio, Xaira Therapeutics! Jointly incubated by Arch Venture Partners and Foresite Labs, and led by renowned scientist Marc Tessier-Lavigne, Xaira emerged from stealth today with $1B in committed capital. Read the exclusive story in Endpoints News.

We're happy to see our colleague Shoman Kasbekar included in this piece in the Biomarker newsletter covering rising stars in biotech investing and creation, how they got started, and lessons learned. Shoman shares his perspective on how the success of the investment only begins with the investment itself. Read more at the link below.